Ge Wei, Hu Pei-Zhen, Huang Yang, Wang Xiao-Ming, Zhang Xiu-Min, Sun Yu-Jing, Li Zeng-Shan, Si Shao-Yan, Sui Yan-Fang
Department of Pathology, State Key Laboratory of Cancer Biology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province 710032, P.R. China.
Oncol Rep. 2009 Oct;22(4):915-20. doi: 10.3892/or_00000517.
Our previous study showed that nanoemulsion-encapsulated MAGE1-HSP70/SEA (MHS) complex protein vaccine elicited MAGE-1 specific immune response and antitumor effects against MAGE-1-expressing tumor and nanoemulsion is a useful vehicle with possible important implications for cancer biotherapy. The purpose of this study was to compare the immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70 and SEA as NE(MHS) vaccine following different administration routes and to find out the new and effective immune routes. Nanoemulsion vaccine was prepared using magnetic ultrasound methods. C57BL/6 mice were immunized with NE(MHS) via po., i.v., s.c. or i.p., besides mice s.c. injected with PBS or NE(-) as control. The cellular immunocompetence was detected by ELISpot assay and LDH release assay. The therapeutic and tumor challenge assay were also examined. The results showed that the immune responses against MAGE-1 expressing murine tumors elicited by NE(MHS) via 4 different routes were approximately similar and were all stronger than that elicited by PBS or NE(-), suggesting that this novel nanoemulsion carrier can exert potent antitumor immunity against antigens encapsulated in it. Especially, the present results indicated that nanoemulsion vaccine adapted to administration via different routes including peroral, and may have broader applications in the future.
我们之前的研究表明，纳米乳剂包裹的MAGE1-HSP70/SEA（MHS）复合蛋白疫苗可引发MAGE-1特异性免疫反应，并对表达MAGE-1的肿瘤产生抗肿瘤作用，且纳米乳剂是一种有用的载体，对癌症生物治疗可能具有重要意义。本研究的目的是比较纳米乳剂包裹的MAGE1-HSP70和SEA作为NE（MHS）疫苗经不同给药途径诱导的免疫反应，并找出新的有效免疫途径。采用磁超声法制备纳米乳剂疫苗。将C57BL/6小鼠经口服、静脉注射、皮下注射或腹腔注射NE（MHS）进行免疫，此外，将小鼠皮下注射PBS或NE（-）作为对照。通过ELISpot试验和LDH释放试验检测细胞免疫能力。还进行了治疗和肿瘤攻击试验。结果表明，NE（MHS）经4种不同途径诱导的针对表达MAGE-1的小鼠肿瘤的免疫反应大致相似，且均强于PBS或NE（-）诱导的反应，这表明这种新型纳米乳剂载体可对包裹其中的抗原发挥强大的抗肿瘤免疫作用。特别是，目前的结果表明，纳米乳剂疫苗适用于包括口服在内的不同途径给药，未来可能具有更广泛的应用。
